Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial

Drug Research

Volumn 65, Issue 11, 2014, Pages 567-573

  Panahi, Y ^a   Ghanei, M ^a   Bashiri, S ^a   Hajihashemi, A ^a   Sahebkar, A ^b,c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

curcumin; cytokine; inflammation; randomized controlled trial; respiratory function; sulfur mustard

Indexed keywords

ACETYLCYSTEINE; C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; CURCUMIN; CURCUMINOID; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MUSTARD GAS; PANTOPRAZOLE; PLACEBO; SALMETEROL; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; BIS(4-HYDROXYCINNAMOYL)METHANE; CHEMICAL WARFARE AGENT; CYTOKINE; DEMETHOXYCURCUMIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GAS POISONING; HEADACHE; HUMAN; IRAN; LUNG FUNCTION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SMELLING DISORDER; SULFUR MUSTARD INTOXICATION; SUPPLEMENTATION; TOTAL LUNG CAPACITY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHRONIC DISEASE; INFLAMMATION; LUNG DISEASES; METABOLISM; PILOT STUDY; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; ANTI-INFLAMMATORY AGENTS; CHEMICAL WARFARE AGENTS; CHRONIC DISEASE; CURCUMIN; CYTOKINES; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG DISEASES; MALE; MIDDLE AGED; MUSTARD GAS; PILOT PROJECTS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84946112043     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0034-1389986     Document Type: Article

References (70)

1. Balali-Mood M., Hefazi M., Mahmoudi M. et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol: 2005; 19 713 721
2. Khateri S., Ghanei M., Keshavarz S. et al. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med: 2003; 45 1136 1143
3. Emad A., Rezaian G. R. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest: 1997; 112 734 738
4. Attaran D., Khajedaloui M., Jafarzadeh R. et al. Health-related quality of life in patients with chemical warfare-induced chronic obstructive pulmonary disease. Arch Iran Med: 2006; 9 359 363
5. Balali-Mood M., Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol: 2006; 99 273 282
6. Ghanei M., Fathi H., Mohammad M. M. et al. Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol: 2004; 16 491 495
7. Vernooy J. H., Kucukaycan M., Jacobs J. A. et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med: 2002; 166 1218 1224
8. Polatli M., Cakir A., Cildag O. et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis: 2008; 26 97 102
9. Tonstad S., Cowan J. L. C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract: 2009; 63 1634 1641
10. Westergren-Thorsson G., Larsen K., Nihlberg K. et al. Pathological airway remodelling in inflammation. Clin Respir J: 2010; 4 01 1 8
11. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol: 2001; 429 195 207
12. Tkacova R., Kluchova Z., Joppa P. et al. Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. Respir Med: 2007; 101 1670 1676
13. Attaran D., Lari S. M., Khajehdaluee M. et al. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Human and experimental toxicology: 2009; 28 739 745
14. Attaran D., Lari S. M., Towhidi M. et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease: 2010; 5 335 340
15. Panahi Y., Davoudi S. M., Sahebkar A. et al. Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: a randomized double-blind clinical trial. Cutaneous and ocular toxicology: 2012; 31 95 103
16. Panahi Y., Ghanei M., Vahedi E. et al. Effect of recombinant human IFNgamma in the treatment of chronic pulmonary complications due to sulfur mustard intoxication. Journal of immunotoxicology: 2013
17. Panahi Y., Sahebkar A., Davoudi S. M. et al. Efficacy and safety of immunotherapy with interferon-gamma in the management of chronic sulfur mustard-induced cutaneous complications: comparison with topical betamethasone 1%. TheScientificWorldJournal: 2012; 2012 285274
18. Panahi Y., Sarayani A., Beiraghdar F. et al. Management of sulfur mustard-induced chronic pruritus: a review of clinical trials. Cutaneous and ocular toxicology: 2012; 31 220 225
19. Sahebkar A. Baicalin as a potentially promising drug for the management of sulfur mustard induced cutaneous complications: a review of molecular mechanisms. Cutaneous and ocular toxicology: 2012; 31 226 234
20. Anand P., Kunnumakkara A. B., Newman R. A. et al. Bioavailability of curcumin: problems and promises. Mol Pharm: 2007; 4 807 818
21. Strimpakos A. S., Sharma R. A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants and redox signaling: 2008; 10 511 545
22. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? BioFactors: 2013; 39 197 208
23. Shehzad A., Khan S., Sup Lee Y. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol: 2012; 8 179 190
24. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertility and sterility: 2010; 94 e75 e76 author reply e7
25. Jurenka J. S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev: 2009; 14 141 153
26. Shehzad A., Ha T., Subhan F. et al. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr: 2011; 50 151 161
27. Shehzad A., Rehman G., Lee Y. S. Curcumin in inflammatory diseases. BioFactors: 2013; 39 69 77
28. Sahebkar A. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis. Phytotherapy research: 2014; 28 633 642
29. Meng B., Li J., Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Current pharmaceutical design: 2013; 19 2101 2113
30. Sahebkar A., Mohammadi A., Atabati A. et al. Curcuminoids Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals. Phytotherapy research: 2013; 27 1883 1888
31. Hossain D. M., Bhattacharyya S., Das T. et al. Curcumin: the multi-targeted therapy for cancer regression. Frontiers in bioscience: 2012; 4 335 355
32. Shehzad A., Wahid F., Lee Y. S. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Archiv der Pharmazie: 2010; 343 489 499
33. Srivastava G., Mehta J. L. Currying the heart: curcumin and cardioprotection. Journal of cardiovascular pharmacology and therapeutics: 2009; 14 22 27
34. Srivastava R. M., Singh S., Dubey S. K. et al. Immunomodulatory and therapeutic activity of curcumin. International immunopharmacology: 2011; 11 331 341
35. Monroy A., Lithgow G. J., Alavez S. Curcumin and neurodegenerative diseases. BioFactors: 2013; 39 122 132
36. Panahi Y., Badeli R., Karami N. et al. Investigation of the Efficacy of Adjunctive Therapy with Bioavailability-Boosted Curcuminoids in Major Depressive Disorder. Phytother Res: 2014; 4 10.1002/ptr.5211
37. Coban D., Milenkovic D., Chanet A. et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Molecular nutrition and food research: 2012; 56 1270 1281
38. Mohammadi A., Sahebkar A., Iranshahi M. et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy research: PTR: 2013; 27 374 379
39. Panahi Y., Khalili N., Hosseini M. S. et al. Lipid-modifying effects of adjunctive therapy with curcuminoids - piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complement Ther Med: 2014; 10.1016/j.ctim.2014.07.006
40. Kunnumakkara A. B., Anand P., Aggarwal B. B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer letters: 2008; 269 199 225
41. Panahi Y., Rahimnia A. R., Sharafi M. et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res: 2014; 10.1002/ptr.5174
42. Ghanei M., Ghayumi M., Ahakzani N. et al. Noninvasive diagnosis of bronchiolitis obliterans due to sulfur mustard exposure: could high-resolution computed tomography give us a clue? La Radiologia medica: 2010; 115 413 420
43. Panahi Y., Ghanei M., Aslani J. et al. The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas. Iranian journal of allergy, asthma, and immunology: 2005; 4 83 90
44. Suzuki M., Betsuyaku T., Ito Y. et al. Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. American journal of physiology Lung cellular and molecular physiology: 2009; 296 L614 L623
45. Venkatesan N. Pulmonary protective effects of curcumin against paraquat toxicity. Life sciences: 2000; 66 PL21 PL28
46. Kalpana C., Menon V. P. Curcumin ameliorates oxidative stress during nicotine-induced lung toxicity in Wistar rats. The Italian journal of biochemistry: 2004; 53 82 86
47. Punithavathi D., Venkatesan N., Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British journal of pharmacology: 2000; 131 169 172
48. Punithavathi D., Venkatesan N., Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. British journal of pharmacology: 2003; 139 1342 1350
49. Vanisree A. J., Sudha N. Curcumin combats against cigarette smoke and ethanol-induced lipid alterations in rat lung and liver. Molecular and cellular biochemistry: 2006; 288 115 123
50. Xu M., Deng B., Chow Y. L. et al. Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. Journal of ethnopharmacology: 2007; 112 292 299
51. Polasa K., Raghuram T. C., Krishna T. P. et al. Effect of turmeric on urinary mutagens in smokers. Mutagenesis: 1992; 7 107 109
52. Sin D. D., Man S. F. Interleukin-6: a red herring or a real catch in COPD? Chest: 2008; 133 4 6
53. Yanbaeva D. G., Dentener M. A., Spruit M. A. et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC medical genetics: 2009; 10 23
54. Emad A., Emad Y. Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. Journal of interferon and cytokine research: the official journal of the International Society for Interferon and Cytokine Research: 2007; 27 38 43
55. Oh S. W., Cha J. Y., Jung J. E. et al. Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-kappaB inhibition. Journal of ethnopharmacology: 2011; 136 414 421
56. Shakibaei M., John T., Schulze-Tanzil G. et al. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochemical pharmacology: 2007; 73 1434 1445
57. Jobin C., Bradham C. A., Russo M. P. et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of immunology: 1999; 163 3474 3483
58. Shishodia S., Amin H. M., Lai R. et al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochemical pharmacology: 2005; 70 700 713
59. Surh Y. J., Chun K. S., Cha H. H. et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation research: 2001; 480-481 243 268
60. Abe Y., Hashimoto S., Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacological research: the official journal of the Italian Pharmacological Society: 1999; 39 41 47
61. Biswas S. K., McClure D., Jimenez L. A. et al. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxidants and redox signaling: 2005; 7 32 41
62. Holroyde M. C., Altounyan R. E., Cole M. et al. Bronchoconstriction produced in man by leukotrienes C and D. Lancet: 1981; 2 17 18
63. Lam S., Chan H., LeRiche J. C. et al. Release of leukotrienes in patients with bronchial asthma. The Journal of allergy and clinical immunology: 1988; 81 711 717
64. Marom Z., Shelhamer J. H., Sun F. et al. Human airway monohydroxyeicosatetraenoic acid generation and mucus release. The Journal of clinical investigation: 1983; 72 122 127
65. Panahi Y., Sahebkar A., Amiri M. et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. The British journal of nutrition: 2012; 108 1272 1279
66. Panahi Y., Sahebkar A., Parvin S. et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Annals of clinical biochemistry: 2012; 49 580 588
67. Cheng A. L., Hsu C. H., Lin J. K. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research: 2001; 21 2895 2900
68. Lao C. D., Ruffin MTt, Normolle D. et al. Dose escalation of a curcuminoid formulation. BMC complementary and alternative medicine: 2006; 6 10
69. Shoba G., Joy D., Joseph T. et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta medica: 1998; 64 353 356
70. Kim D. H., Phillips J. F., Lockey R. F. Oral curcumin supplementation in patients with atopic asthma. Allergy and rhinology: 2011; 2 e51 e53